Infliximab Control ( DrugBank: Infliximab )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 1 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00394589 (ClinicalTrials.gov) | March 2006 | 31/10/2006 | Re³ (Re-Cube: Retain Remicade® Response)(Study P04249AM3) | Randomised Controlled Trial Evaluating Strategies to Optimize Disease Activity Control in RA Patients Treated With Infliximab in Clinical Practice. | Rheumatoid Arthritis | Drug: Infliximab Control;Drug: Infliximab Increased Frequency;Drug: Infliximab Increased Dose | Merck Sharp & Dohme Corp. | Integrated Therapeutics Group | Terminated | 18 Years | N/A | All | 43 | Phase 3 | Austria;Belgium;Denmark;France;Germany;Netherlands;Sweden;Turkey |